Key Takeaways
- Volume-led recovery, margin rebound: Standalone EBITDA margin jumped to 25% (vs 21% QoQ) on stabilized input costs and higher volumes, while consolidated volume grew 8.25% YoY.
- Specialty chemicals still a drag: Acetonitrile plant remains closed, DMF runs at 35-40% capacity, and Chinese recycled NMP/GBL material continues to suppress virgin demand, keeping the specialty portfolio below potential.
- New product pipeline advancing: n-Butylamines production commenced, methylamines plant targets December 2024 commissioning, and R&D has cracked diethanolamine-based technology to shift EDA output toward higher-value derivatives.
- Battery-chemical bets await customers: DMC and propylene glycol plants run at 30-40% utilization because lithium-battery companies have talked for 4-5 years but "nobody has done kickstart"; NMP demand hinges on 1-2 front-runner battery companies materializing.
- What to watch next quarter: Whether the methylamines plant commissions on schedule, any progress on battery-chemical offtake, and if the EDA plant's new value-added product mix shows up in commercial volumes.
Volume & Margin Recovery
- Volume growth delivered: Consolidated volume improved 8.25% YoY, driven by demand recovery as destocking eased on the Indian side and Chinese competition softened, with prices moving favorably for India.
- Margin bounce explained: Q4 standalone EBITDA margin reached 25% vs 20% in Q3, powered by stabilized raw material and utility costs plus higher volume uptake; the improvement came from a combination of both methyl and ethyl chain products, not one specific chain.
- Normalized margin baseline: Excluding the COVID bonus period of FY22-23, normal EBITDA levels were 21-22%; this year delivered 21% yearly despite specialty underperformance, and management says if specialty adds, margins would reach 23-24%.
- DMF viability improving: At the current price of ₹70/kg, DMF is workable at lower margin; at ₹100/kg it was viable even buying DMA from outside, and with own DMA from the new methylamines plant, the DMF plant will operate fully.
Reddy: "Minimum 10%, I'm telling you. I'm telling you very conservatively, but minimum 10% without considering any expansions."
Specialty Chemicals: What's Weighing
- Acetonitrile plant closed: The plant is totally shut, and while technology remains in the pipeline, it has not been prioritized due to other projects; management may revive it if the market improves or may develop other products on the same asset after routine expansions.
- DMF capacity chronically underused: The DMF plant historically operated at 70-80% capacity for only 1-1.5 years; otherwise it runs at 35-40%, partly because DMA availability sometimes restricts production, and management chooses whichever product is more profitable at the time.
- Chinese recycled material hurting NMP/GBL: Recycled material from China, after 2-3 uses in electronics, entered the market; simple purification shows 99.9% purity but large metal impurities remain untested, and this is impacting demand for virgin material.
- 2P demand recovering: 2P has been going full-fledged from last quarter onwards, and PVP K is operating at 100% level.
- FDA catalyst uncertain: Management noted that FDA may become alert about recycled material impurities, which could change the market, but no timeline or signal exists.
Expansion Projects & New Products
Methylamines & DMF integration
- Methylamines plant: Commissioning likely around end of December 2024; once operational, both the methylamines plant and the DMF plant will run at 100% capacity, with own DMA supply removing the bottleneck.
- DMF exports begun: Small export volumes have started, including to Saudi Arabia and some containers to Europe; discussions with the US are also underway.
EDA plant & value-added shift
- Current low utilization explained: The EDA plant operated at only 42% vs 72% last year because every month roughly 1-1.5 weeks are spent on development work for new technology to get more value-added products like DETA, PIP, TETA, TEPA, and PEHA.
- R&D breakthrough: R&D has reached final conclusion on using a diethanolamine combination to increase output of value-added derivatives; management expects less EDA coming to market and more value-added products visible in the coming 1-2 quarters.
- Piperazine potential: If R&D works the same at commercial scale, management expects 400-500 tons per month, converting to roughly 5,000 tons annually, equivalent to the country's entire consumption.
Other product launches
- n-Butylamines: Production successfully commenced at Unit IV, boosting annual installed capacity by 15,000 metric tons; capacity is double Indian consumption, and plans exist for captive consumption in coming years.
- N-Methyl Morpholine: Proposed at 3,000 tons per annum.
- NBPT: Proposed at 2,500 tons per annum.
- Isopropylamine: Proposed to manufacture Mono and Di in the existing Ethylamine plant at Unit I by modifying it; the plant is not in operations because a new high-output Ethylamine plant was set up at Unit IV.
BSC Unit 2 progress
- Environmental clearance: TOR already received; environmental clearance expected by end of May 2024 or first/second week of the next month.
- First-phase products: Sodium cyanide (first product), triethyl orthoformate, hydrogen cyanide, EDTA, EDTA acetic acid, Benzyl Cyanide (BnCN), Phenylacetic Acid (PAA), triethyl orthoformate, and trimethyl orthoformate.
- Debottlenecking ongoing: Will continue in the coming 1-2 quarters; capacity improvement and combination improvement will be visible.
Reddy: "It's too early to say, but definitely, it should cross INR 1,000 crores minimum with this unit 2 alone."
Battery Chemicals: Waiting for Customers
- DMC/propylene glycol plants underutilized: Operating at only 30-40% because these plants were meant for lithium batteries; battery companies talked for 4-5 years but nobody has kickstarted, though 1-2 serious companies have now visited the plant.
- NMP demand tied to battery adoption: Management expects a lot of consumption from lithium battery companies in the coming 1-2 years; if 1-2 front-runner battery companies come, NMP capacity will go to 100%.
- Electronic grade DMC: Plant set to commission in FY 2024-25; holds promising prospects in India's EV battery market due to exclusive production status.
- DMC fallback: If battery offtake does not materialize, DMC will serve pharma and agro markets.
Reddy: "See, it is operating presently 30% to 40%. You are well aware these plants were meant for the lithium batteries. Actually, lithium batteries companies, last 4-5 years, they were talking. Last 4-5 years. Just in they were coming like this, they were talking. But unfortunately, nobody has done kickstart."
Energy & Infrastructure
- Solar power plant: 20 MW captive solar park with MIDC Solapur, Maharashtra; Phase 1 of 8 MW expected operational by December 2024, which will take care of 60-70% of the power bill; full 20 MW will cover all expansions and upcoming plants.
- 100% solar ambition: Management stated the day will come when 100% of power is utilized from solar only.
- Dimethyl ether opportunity: The Government of India has a plan to make it mandatory for all LPG manufacturers to blend 20% dimethyl ether; the notification has come and is under publication; Balaji's DME manufacturing project at Unit IV is set to launch by March 2025.
- Hotel expansion: Adding 40 rooms toward the south side of the existing structure, costing ₹30-35 crore.
- Debottlenecking at Unit I: Not yet complete; 2-3 more months of shutdowns needed; R&D has developed the ability to use diethanolamine instead of monoethanolamine for product mix development.
Reddy: "Dimethyl ether, we don't have the license, but the Government of India is having a plan that they are going to make it mandatory to all the LPG manufacturers that they should blend 20% of dimethyl ether, mandatorily. That time, we will have the advantage as being a first manufacturer."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Standalone volume growth | Minimum 10%, conservatively, without considering any expansions | FY25 |
| Consolidated EBITDA margin | 21% to 24% range | FY25 |
| Methylamines plant commissioning | Plant operational, DMF and methylamines both at 100% capacity | End of December 2024 |
| Electronic grade DMC plant | Commissioning | FY 2024-25 |
| Dimethyl ether manufacturing project | Launch at Unit IV | By March 2025 |
| Solar Phase 1 (8 MW) | Operational, covering 60-70% of power bill | December 2024 |
| EDA value-added product shift | Less EDA to market, more DETA/PIP/TETA/TEPA/PEHA visible | Coming 1-2 quarters |
| BSC Unit 2 environmental clearance | Expected receipt | End of May 2024 or early June 2024 |
| Unit I debottlenecking | Completion of shutdowns | 2-3 months |
| Hotel expansion | 40 rooms added at ₹30-35 cr cost | Not specified |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Consolidated revenue from operations | ₹423 cr, vs ₹392 cr in Q3 FY24 |
| Standalone revenue from operations | ₹373 cr, vs ₹314 cr in Q3 FY24 |
| Consolidated EBITDA | ₹106 cr, vs ₹83 cr in Q3 FY24 |
| Consolidated EBITDA margin | 25%, vs 21% in Q3 FY24 |
| Standalone EBITDA margin | 25%, vs 20% in Q3 FY24 |
| Consolidated PAT | ₹72 cr, vs ₹56 cr in Q3 FY24 |
| Consolidated diluted EPS | ₹21 per share, vs ₹15.24 in Q3 FY24 |
| Total volume | 27,984 metric tons, vs 26,903 metric tons in Q3 FY24 |
| Amines volumes | 8,910 metric tons |
| Amines derivatives volumes | 9,676 metric tons |
| Specialty Chemical volumes | 9,398 metric tons |
| Standalone volume growth guidance for FY25 | Minimum 10%, without considering any expansions |
| EBITDA margin guidance | 21% to 24% |
| DMF capacity utilization outlook | More than 70%, from Q1 FY25 onwards |
| DMC and propylene glycol plant capacity utilization | 30% to 40% |
| EDA plant capacity utilization in FY24 | 42%, vs 72% last year |
| Hotel occupancy | 85% to 90% |